Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

Dublin, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The "Budesonide Inhaler Market Research Report by Dosage, by Products Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has ...

Budesonide (Budecort Inhaler) is a corticosteroid, prescribed for inflammatory bowel disease, asthma, and also for breathing trouble. Budesonide is indicated for: 1. Treatment of Mild to Moderate ...

Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

Add Yahoo as a preferred source to see more of our stories on Google. A new study shows that a dual-action inhaler cuts asthma attacks in children almost in half. (CREDIT: Imperial College London) For ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Inhaled budesonide twice daily administered early in the ...

The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...

Inhaled budesonide (Pulmicort), commonly used in asthma, helped COVID-19 outpatients at extra risk for severe illness recover more quickly relative to standard care in the pragmatic PRINCIPLE trial, ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

Concerns remain about the safety of adding long-acting β 2-agonists to inhaled glucocorticoids for the treatment of asthma. In a postmarketing safety study mandated by the Food and Drug Administration ...